Cargando…
Protein-based vehicles for biomimetic RNAi delivery
Broad translational success of RNA interference (RNAi) technology depends on the development of effective delivery approaches. To that end, researchers have developed a variety of strategies, including chemical modification of RNA, viral and non-viral transfection approaches, and incorporation with...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6390323/ https://www.ncbi.nlm.nih.gov/pubmed/30891095 http://dx.doi.org/10.1186/s13036-018-0130-7 |
_version_ | 1783398119424131072 |
---|---|
author | Pottash, Alex Eli Kuffner, Christopher Noonan-Shueh, Madeleine Jay, Steven M. |
author_facet | Pottash, Alex Eli Kuffner, Christopher Noonan-Shueh, Madeleine Jay, Steven M. |
author_sort | Pottash, Alex Eli |
collection | PubMed |
description | Broad translational success of RNA interference (RNAi) technology depends on the development of effective delivery approaches. To that end, researchers have developed a variety of strategies, including chemical modification of RNA, viral and non-viral transfection approaches, and incorporation with delivery vehicles such as polymer- and lipid-based nanoparticles, engineered and native proteins, extracellular vesicles (EVs), and others. Among these, EVs and protein-based vehicles stand out as biomimetically-inspired approaches, as both proteins (e.g. Apolipoprotein A-1, Argonaute 2, and Arc) and EVs mediate intercellular RNA transfer physiologically. Proteins specifically offer significant therapeutic potential due to their biophysical and biochemical properties as well as their ability to facilitate and tolerate manipulation; these characteristics have made proteins highly successful translational therapeutic molecules in the last two decades. This review covers engineered protein vehicles for RNAi delivery along with what is currently known about naturally-occurring extracellular RNA carriers towards uncovering design rules that will inform future engineering of protein-based vehicles. |
format | Online Article Text |
id | pubmed-6390323 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-63903232019-03-19 Protein-based vehicles for biomimetic RNAi delivery Pottash, Alex Eli Kuffner, Christopher Noonan-Shueh, Madeleine Jay, Steven M. J Biol Eng Review Broad translational success of RNA interference (RNAi) technology depends on the development of effective delivery approaches. To that end, researchers have developed a variety of strategies, including chemical modification of RNA, viral and non-viral transfection approaches, and incorporation with delivery vehicles such as polymer- and lipid-based nanoparticles, engineered and native proteins, extracellular vesicles (EVs), and others. Among these, EVs and protein-based vehicles stand out as biomimetically-inspired approaches, as both proteins (e.g. Apolipoprotein A-1, Argonaute 2, and Arc) and EVs mediate intercellular RNA transfer physiologically. Proteins specifically offer significant therapeutic potential due to their biophysical and biochemical properties as well as their ability to facilitate and tolerate manipulation; these characteristics have made proteins highly successful translational therapeutic molecules in the last two decades. This review covers engineered protein vehicles for RNAi delivery along with what is currently known about naturally-occurring extracellular RNA carriers towards uncovering design rules that will inform future engineering of protein-based vehicles. BioMed Central 2019-02-26 /pmc/articles/PMC6390323/ /pubmed/30891095 http://dx.doi.org/10.1186/s13036-018-0130-7 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Review Pottash, Alex Eli Kuffner, Christopher Noonan-Shueh, Madeleine Jay, Steven M. Protein-based vehicles for biomimetic RNAi delivery |
title | Protein-based vehicles for biomimetic RNAi delivery |
title_full | Protein-based vehicles for biomimetic RNAi delivery |
title_fullStr | Protein-based vehicles for biomimetic RNAi delivery |
title_full_unstemmed | Protein-based vehicles for biomimetic RNAi delivery |
title_short | Protein-based vehicles for biomimetic RNAi delivery |
title_sort | protein-based vehicles for biomimetic rnai delivery |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6390323/ https://www.ncbi.nlm.nih.gov/pubmed/30891095 http://dx.doi.org/10.1186/s13036-018-0130-7 |
work_keys_str_mv | AT pottashalexeli proteinbasedvehiclesforbiomimeticrnaidelivery AT kuffnerchristopher proteinbasedvehiclesforbiomimeticrnaidelivery AT noonanshuehmadeleine proteinbasedvehiclesforbiomimeticrnaidelivery AT jaystevenm proteinbasedvehiclesforbiomimeticrnaidelivery |